Early versus late stage schizophrenia. What markers make the difference?

Area of Science:

• Psychiatry
• Neuroscience
• Immunology

Background:

• Schizophrenia (SCH) is a chronic mental disorder with varying progression. Differentiating early-stage (ESSCH) from late-stage (LSSCH) is crucial for targeted interventions.
• Understanding the distinct psychopathological, cognitive, functional, physical health, and inflammatory profiles of ESSCH and LSSCH can inform treatment strategies.

Purpose of the Study:

• To identify specific markers that differentiate between early-stage schizophrenia (ESSCH) and late-stage schizophrenia (LSSCH).
• To investigate psychopathological, cognitive, functional, physical health, and inflammatory differences between ESSCH and LSSCH.

Main Methods:

• A cross-sectional, naturalistic study involving 104 patients with schizophrenia, divided into ESSCH (≤7 years illness duration) and LSSCH (>10 years illness duration).
• Statistical analyses included chi-square tests, Student's t-tests, ANCOVA, and binomial logistic regression, controlling for age, sex, BMI, and smoking.
• Key variables assessed were psychopathology, cognitive function, physical health, and inflammatory markers like IκBα.

Main Results:

• ESSCH patients demonstrated greater negative symptom severity and lower levels of IκBα compared to LSSCH patients.
• A higher proportion of ESSCH patients were classified as normal weight (40% vs 18.8%).
• Binomial logistic regression identified age and IκBα as significant differentiators, with the model accounting for 38.9% of the variance.

Conclusions:

• Age and IκBα levels are unique markers distinguishing ESSCH from LSSCH.
• These findings support the hypothesis of illness episode toxicity in schizophrenia.
• Preventing new illness episodes is highlighted as critical for managing schizophrenia progression.